Shufersal to pay NIS 130m for New-Pharm

New-Pharm  photo: PR

Shufersal will repay a debt secured on the shares being bought. The deal now requires regulatory approval.

Supermarket chain Shufersal Ltd. (TASE:SAE) announced this morning that it was buying the New-Pharm Drugstores Ltd. drugstore chain from Hamashbir 365 Holdings for NIS 130 million. The consideration includes repayment of a debt of Hamashbir 365 secured on the shares being ought and a payment of NIS 12 million for repayment of a debt owed by a Hamashbir 365 subsidiary to New-Pharm.

The question that now arises is whether the Antitrust Commissioner will approve the deal. The sale agreement states that if regulatory approval is not obtained within three months from the date it is requested, the agreement will be void, unless the parties agree to extend it.

New-Pharm was founded in 1992, and operates 67 branches that, besides containing pharmacies, sell cosmetics, toiletries, baby products, household wares, natural healthcare products, and so on. It employs about 1,100 people.

According to figures released by Hamashbir 365, New-Pharm had NIS 711 million revenue in 2016, 3% more than in 2015, and made a pre-tax loss of NIS 22 million.

Published by Globes [online], Israel business news - www.globes-online.com - on April 9, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017.

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
New-Pharm  photo: PR
New-Pharm photo: PR
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017